Daiichi Sankyo to pay 8% royalty to Seagen in ADC patent row

Japanese drugmaker Daiichi Sankyo (TYO: 4568) revealed that it has been ordered by a Texas district court to pay royalties on its antibody-drug conjugate (ADC) to US biotech Seagen (Nasdaq: SGEN).

The District Court’s amended final judgment requires Daiichi Sankyo to pay Seagen a royalty of 8% on sales of Enhertu (fam-trastuzumab deruxtecan-nxki) from April 1, 2022 through November 4, 2024 (the expiry of US Patent 10,808,039) in addition to the $41.8 million in damages previously awarded by the Court following the jury’s verdict.

The District Court entered the amended final judgment after its denial of Daiichi Sankyo’s motions for judgment as a matter of law, or alternatively, a new trial, and its resolution of motions seeking clarification of prior orders. Daiichi Sankyo had made those motions in response to the April 8, 2022 jury verdict. The District Court also denied Seagen’s request for attorneys’ fees.